Pembrolizumab (Keytruda®) accepted for restricted use within NHS Scotland for metastatic or unresectable recurrent head and neck squamous cell carcinoma

Pembrolizumab intravenous infusion is approved as monotherapy or in combination with platinum and fluorouracil chemotherapy, in adults whose tumours express programmed cell death ligand-1 with a combined positive score ≥1 and subject to a two-year clinical stopping rule.


Scottish Medicines Consortium